低分子量肝素、硫酸镁联合治疗早发型子痫前期的临床疗效分析

Clinical Analysis of Low Molecular Weight Heparin and Magnesium Sulfate in Treating Early-onset Preeclampsia

目的探讨低分子量肝素、硫酸镁联合治疗早发型子痫前期的临床疗效。方法回顾2015年2月—2016年9月84例早发型子痫前期产妇并分组。对照组采用硫酸镁进行治疗,联合组采用低分子量肝素、硫酸镁联合治疗。比较效果。结果联合组早发型子痫前期临床疗效高于对照组,P<0.05;联合组胎儿窘迫、新生儿窒息、胎盘早剥、产后出血等母婴不良结局发生率低于对照组,P<0.05;干预前两组血浆D-二聚体、血压监测水平相近,P>0.05;干预后联合组血浆D-二聚体、血压监测水平优于对照组,P<0.05。结论低分子量肝素、硫酸镁联合治疗早发型子痫前期的临床疗效确切,可改善产妇血压、纤溶系统及母婴结局。

Objective To investigate the clinical effcacy of low molecular weight heparin and magnesium sulfate in the treatment of early-onset preeclampsia. Methods From February 2015 to September 2016, 84 pregnant women with early-onset preeclampsia were reviewed and divided into two groups. The control group was treated with magnesium sulfate, and the combination group was treated with low molecular weight heparin and magnesium sulfate. The effect was compared. Results The clinical effcacy of early onset preeclampsia in the combined group was higher than that ofthe control group （P 〈 0.05）. The incidence of maternal and fetal adverse outcomes such as fetal distress, neonatal asphyxia, placental abruption and postpartum hemorrhage in the combined group was lower than that in the control group （P 〈 0.05）. Plasma D-dimer levels were similar in the two groups before intervention （P 〉 0.05）; plasma D-dimer level and blood pressure monitoring level in the combined group was better than those in the control group （P 〈 0.05）. Conclusion Low molecular weight heparin, magnesium sulfate combined treatment of early onset of preeclampsia can obtain good clinical curative effect, and can improve maternal blood pressure, fbrinolytic system and maternal and infant outcomes.